A subscription to JoVE is required to view this content. Sign in or start your free trial.
To investigate the immune response to brain disorders, one common approach is to analyze changes in immune cells. Here, two simple and effective protocols are provided for isolating immune cells from murine brain tissue and skull bone marrow.
Mounting evidence indicates that the immune response triggered by brain disorders (e.g., brain ischemia and autoimmune encephalomyelitis) occurs not only in the brain, but also in the skull. A key step toward analyzing changes in immune cell populations in both the brain and skull bone marrow after brain damage (e.g., stroke) is to obtain sufficient numbers of high-quality immune cells for downstream analyses. Here, two optimized protocols are provided for isolating immune cells from the brain and skull bone marrow. The advantages of both protocols are reflected in their simplicity, speed, and efficacy in yielding a large quantity of viable immune cells. These cells may be suitable for a range of downstream applications, such as cell sorting, flow cytometry, and transcriptomic analysis. To demonstrate the effectiveness of the protocols, immunophenotyping experiments were performed on stroke brains and normal brain skull bone marrow using flow cytometry analysis, and the results aligned with findings from published studies.
The brain, the central hub of the nervous system, is protected by the skull. Beneath the skull are three layers of connective tissue known as the meninges - the dura mater, arachnoid mater, and pia mater. Cerebrospinal fluid (CSF) circulates in the subarachnoid space between the arachnoid mater and pia mater, cushioning the brain and also removing waste via the glymphatic system1,2. Together, this unique architecture provides a secure and supportive environment that maintains the stability of the brain and shields it from potential injury.
The brain has long been considered immune-privileged. However, this notion has been partially abandoned as mounting evidence indicates that, in addition to resident microglia in the parenchyma, the borders of the brain, including the choroid plexus and meninges, host a diverse array of immune cells3. These cells play critical roles in maintaining homeostasis, surveilling brain health, and initiating the immune response to brain injury. Notably, recent findings indicate that the skull is involved in meninges immunity, and may contribute to the immune response in the brain after injury. In 2018, Herisson et al. made a seminal discovery of direct vascular channels that link the skull bone marrow to the meninges, thereby establishing an anatomical route for leukocyte migration4,5. Later, Cugurra et al. demonstrated that many myeloid cells (e.g., monocytes and neutrophils) and B cells in the meninges do not originate from the blood6. Using techniques such as calvaria bone-flap transplantation and selective irradiation regimens, the authors provided compelling evidence that the skull bone marrow serves as a local source for myeloid cells in the meninges as well as CNS parenchyma after CNS injury6. Further, another study proposed that meningeal B cells are constantly supplied by the skull bone marrow7. More recently, a novel structure, termed the arachnoid cuff exit (ACE), has been identified as a direct gateway between the dura mater and the brain for immune cell trafficking8.
These exciting findings have important implications for the origin of infiltrating immune cells into the injured brain (e.g., after ischemic stroke). A large body of evidence has indicated that after stroke, many immune cells infiltrate the brain, contributing to both acute brain damage and chronic brain recovery. The conventional notionΒ is that these cells are circulating leukocytes in the blood that infiltrate the brain, which is largely facilitated by stroke-induced blood-brain barrier damage. However, this notion has been challenged. In one study, immune cells in the skull and the tibia of mice were labeled differently, and at 6 h after stroke, a significantly greater decrease in neutrophils and monocytes was found in the skull vs. the tibia, and more skull-derived neutrophils were present in the ischemic brain. These data suggest that in the acute stroke phase, neutrophils in the ischemic brain primarily originate from the skull bone marrow4. Interestingly, CSF may guide this migration. Indeed, two recent reports demonstrated that CSF can directly relay signaling cues from the brain into the skull bone marrow via skull channels, and instruct cell migration and hematopoiesis in the skull bone marrow after CNS injury9,10.
In light of these recent findings, it has become important to analyze changes in immune cells in both the brain and the skull bone marrow, when studying the immune response to brain disorders. In such investigations, sufficient numbers of high-quality immune cells are needed for downstream analyses such as cell sorting, flow cytometry analysis, and single-cell RNA sequencing (scRNA-seq). Here, the overall goal is to present two optimized procedures for preparing single-cell suspensions from brain tissue and skull bone marrow. It is important to note that the calvaria (frontal bone, occipital bone, and parietal bones) of the skull are typically used to extract bone marrow, and this bone marrow is specifically referred to as skull bone marrow throughout this study.
The protocol was approved by the Duke Institute Animal Care and Use Committee (IACUC). Male C57Bl/6 mice (3-4 months old; 22-28 g) were used in the current study. The details of the reagents and the equipment used are listed in the Table of Materials.
1. Single-cell suspension from mouse brain
NOTE: Figure 1 illustrates the overview of the brain cell isolation protocol.
2. Preparation of bone marrow single-cell suspension from mouse calvaria
NOTE: Figure 2 depicts the overview of the skull bone marrow isolation procedure.
To prepare immune cells from the mouse brain tissue, the protocol generally yields cells with high viability (84.1%Β Β± 2.3% [meanΒ Β± SD]). Approximately 70%-80% of these cells are CD45 positive. In the normal mouse brain, nearly all CD45+ cells are microglia (CD45LowCD11b+), as expected. This protocol has been used in the laboratory for various applications, including flow cytometry analysis, fluorescence-activated cell sorting (FACS), and scRNA-seq analysis. As an examp...
Here, two simple yet effective protocols are presented for isolating immune cells from the brain and skull bone marrow. These protocols can reliably yield a large quantity of viable immune cells that may be suitable for diverse downstream applications, in particular for flow cytometry.
To study neuroinflammation in various brain disorders, many protocols for immune cell preparations from the brain have been established and used in different laboratories15,
None.
We thank Kathy Gage for her excellent editorial contribution. The illustrationΒ figures wereΒ created with BioRender.com. This study was supported by funds from the Department of Anesthesiology (Duke University Medical Center) and NIH grants NS099590, HL157354, and NS127163.
Name | Company | Catalog Number | Comments |
0.5 mL microcentrifuge tubes | VWR | 76332-066 | |
1.5 mL microcentrifuge tubes | VWR | 76332-068 | |
15 mL conical tubes | Thermo Fisher Scientific | 339651 | |
18 G x 1 in BD PrecisionGlide Needle | BD Biosciences | 305195 | |
1x HBSS | Gibco | 14175-095 | |
50 mL conical tubes | Thermo Fisher Scientific | 339653 | |
96-well V-bottom microplateΒ | SARSTEDT | 82.1583 | |
AURORAΒ flow cytometer | Cytek bioscience | ||
BSA | Fisher | BP9706-100 | |
CD11b-AF594 | BioLegend | 101254 | 1:500 dilution |
CD19-BV785 | BioLegend | 115543 | 1:500 dilution |
CD19-FITC | BioLegend | 115506 | 1:500 dilution |
CD3-APC | BioLegend | 100312 | 1:500 dilution |
CD3-PE | BioLegend | 100206 | 1:500 dilution |
CD45-Alex 700 | BioLegend | 103128 | 1:500 dilution |
CD45-BV421 | Biolegend | 103133 | 1:500 dilution |
Cell Strainer 70 um | Avantor | 732-2758 | |
Dressing ForcepsΒ | V. Mueller | NL1410 | |
EDTA | Invitrogen | 15575-038 | |
Fc Block | Biolegend | 101320 | 1:100 dilution |
Forceps | Roboz | RS-5047 | |
LIVE/DEAD Fixable Blue Dead Cell Stain Kit | Thermo Fisher Scientific | N7167 | 1:500 dilution |
Ly6G-BV421 | BioLegend | 127628 | 1:500 dilution |
Ly6G-PerCp-cy5.5 | BioLegend | 127615 | 1:500 dilution |
NK1.1-APC-cy7 | BioLegend | 108723 | 1:500 dilution |
Percoll (density gradient medium) | Cytiva | 17089101 | |
Phosphate buffer saline (10x) | Gibco | 70011-044 | |
RBC Lysis Buffer (10x) | BioLegend | 420302 | |
Scissors | SKLAR | 64-1250 | |
WHEATON Dounce Tissue, 15 mL Size | DWK Life Sciences | 357544 |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright Β© 2025 MyJoVE Corporation. All rights reserved